Bionpharma

Executive Summary

Bionpharma is a privately held US-based pharmaceutical company founded in 2014 and headquartered in Princeton, NJ. The company specializes in the development, manufacturing, and commercialization of generic and specialty pharmaceutical products, with a particular focus on affordable generic drugs and over-the-counter (OTC) products. Bionpharma has established itself as a major US supplier of softgel capsules and markets a line of OTC products directly to consumers under the A+ Health brand on Amazon. Despite a modest public profile, the company has secured at least one FDA approval and has a commercial product in the market, indicating a foundational capability in regulatory and commercial execution. With a lean operational footprint, Bionpharma is positioned to capitalize on the growing demand for generic medications and consumer OTC healthcare products, though its limited scale and private status constrain visibility into its financial performance and pipeline. The company's focus on e-commerce distribution via Amazon differentiates it from traditional generic players and may offer a scalable channel for consumer health products.

Upcoming Catalysts (preview)

• Q3 2026Launch of new generic drug products (ANDA approvals)60% success
• Q2 2026Expansion of A+ Health OTC brand on Amazon with new product lines70% success
• TBDPotential strategic partnership or acquisition to broaden product portfolio30% success